Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects.
Yasmin Schmid, Anna Rickli, Antonia Schaffner, Urs Duthaler, Eric Grouzmann, Cédric M. Hysek, Matthias E. Liechti
Journal of Pharmacology and Experimental Therapeutics April 2015 DOI: 10.1124/jpet.114.222356 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Double-blind, placebo-controlled, crossover pharmacodynamic and pharmacokinetic study Peer reviewed |
|---|---|
| Sample size | 16 |
| Population | Healthy human subjects |
| Interventions | MDMA Bupropion |
| Topics | MDMA |
| Key points | Bupropion reduced MDMA-induced increases in plasma norepinephrine and heart rate but increased plasma MDMA concentrations and prolonged MDMA's subjective effects; MDMA also increased plasma bupropion concentrations. The authors state this indicates a role for transporter-mediated norepinephrine release in MDMA's cardiostimulant effects but does not support a modulatory role for dopamine in MDMA's mood effects. |
Abstract
3,4-Methylenedioxymethamphetamine (MDMA; "ecstasy") is a popular recreational drug. The aim of the present study was to explore the role of dopamine in the psychotropic effects of MDMA using bupropion to inhibit the dopamine and norepinephrine transporters through which MDMA releases dopamine and norepinephrine by investigating. The pharmacodynamic and pharmacokinetic interactions between bupropion and MDMA in 16 healthy subjects were investigated using a double-blind, placebo-controlled, crossover design. Bupropion reduced the MDMA-induced elevations in plasma norepinephrine concentrations and the heart rate response to MDMA. In contrast, bupropion increased plasma MDMA concentrations and prolonged its subjective effects. Conversely, MDMA increased plasma bupropion concentrations. These results indicate a role for the transporter-mediated release of norepinephrine in the cardiostimulant effects of MDMA but do not support a modulatory role for dopamine in the mood effects of MDMA. These results also indicate that the use of MDMA during therapy with bupropion may result in higher plasma concentrations of both MDMA and bupropion and enhanced mood effects but also result in lower cardiac stimulation.
Comparable studies
Other randomized controlled trials on MDMA, most cited first.
Citations in the library
Cited by 31
- Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms Pharmacological Reviews December 16, 2020
- Safety pharmacology of acute MDMA administration in healthy subjects Journal of Psychopharmacology February 21, 2017
- Acute Effects of Lysergic Acid Diethylamide on Circulating Steroid Levels in Healthy Subjects Journal of Neuroendocrinology February 6, 2016
- Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine ACS Chemical Neuroscience July 12, 2018
- Multifaceted empathy of healthy volunteers after single doses of MDMA: A pooled sample of placebo-controlled studies Journal of Psychopharmacology April 3, 2017
and 26 more in the library
Cites 14
- Duloxetine Inhibits Effects of MDMA (“Ecstasy") In Vitro and in Humans in a Randomized Placebo-Controlled Laboratory Study PLoS One May 4, 2012
- Differential effects of MDMA and methylphenidate on social cognition Journal of Psychopharmacology July 22, 2014
- The Norepinephrine Transporter Inhibitor Reboxetine Reduces Stimulant Effects of MDMA (“Ecstasy”) in Humans Clinical Pharmacology & Therapeutics June 15, 2011
- The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3, 4-methylenedioxymethamphetamine (‘Ecstasy’) in healthy volunteers Journal of Psychopharmacology May 1, 2000
- Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination The International Journal of Neuropsychopharmacology October 8, 2013
and 9 more in the library